How do companies develop a strategy that is both low cost and differentiated without being squeezed in the middle? Describes how to Teva, Israel’s largest and first multinational, achieved its dominant global position in generic pharmaceuticals, an industry that has undergone significant change over the last 20 years. Examines Teva strategies to rise against the two low-cost competition from India and other emerging markets as well as Big Pharma companies that assumption defend … Read more »

How do companies develop a strategy that is both low cost and differentiated without being squeezed in the middle? Describes how to Teva, Israel’s largest and first multinational, achieved its dominant global position in generic pharmaceuticals, an industry that has undergone significant change over the last 20 years. Examines Teva strategies to defend themselves against the two low-cost competition from India and other emerging markets as well as Big Pharma companies adopting increasingly aggressive tactics in generics.
«Hide

from
Tarun Khanna,
Krishna G. Palepu
Source: Video Supplement
1 minute.
Publication Date: Nov 13, 2007. Prod #: 708 807-VIN-ENG
Teva Pharmaceutical Industries, Ltd., VHS HBR case solution

[related_post themes="flat"]